AN2 Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2024 Annual Meeting of Stockholders held by AN2 Therapeutics, Inc. on June 19, 2024. The company is incorporated in Delaware and its common stock trades on The Nasdaq Global Select Market under the symbol ANTX.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting outcomes.
Material Changes and Voting Results
Stockholders representing 78.31% of outstanding shares (23,360,239 shares) attended the meeting, establishing a quorum. Three proposals were voted upon:
- Proposal 1: Election of Class II Directors. Stockholders elected Margaret FitzPatrick, Patricia Martin, and Melvin Spigelman, M.D. to serve until the 2027 annual meeting. All three nominees received significant support with over 17.7 million votes "For" each.
- Proposal 2: Ratification of Auditors. Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. The proposal passed with 23,344,330 votes "For" versus 12,786 "Against".
- Proposal 3: Amendment to Certificate of Incorporation. Stockholders approved an amendment to provide for the exculpation of officers to the extent permitted by Delaware law. The proposal passed with 18,416,318 votes "For" versus 1,292,459 "Against".
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, management outlook, specific risks, or contingencies beyond the standard disclosure of voting results.
Key Facts for Investor Verification
- Verify the effective date and specific language of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) regarding officer exculpation.
- Confirm the tenure of the newly elected Class II directors (FitzPatrick, Martin, Spigelman) through the 2027 annual meeting.
- Review the definitive proxy statement (Schedule 14A filed April 26, 2024) for detailed background on the proposals and director biographies.
- Note that the filing contains no updated financial performance data; refer to the most recent 10-K or 10-Q for financial status.